Biovica’s DiviTum®TKa in four posters at SABCS

2020-10-23 08:00

Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world's largest breast cancer symposium, SABCS, in early December.

The abstracts are based on international studies including the comprehensive US SWOG study, the European prospective PYTHIA study, the PROMISE study at the Mayo Clinic and a dosing study of palbociclib at Washington University. In all studies, DiviTum®TKa has been used to monitor the treatment effect in women with metastatic breast cancer.

“It is extremely gratifying that DiviTum®TKa is included in four posters at SABCS. It is an important validation of our test as a possible standard tool in the evaluation of treatment effect in metastatic breast cancer. The results from the SWOG study are the backbone of our ongoing FDA 510 (k) application with the goal of making the test available to US patients in early 2021,” said Anders Rylander, CEO of Biovica.

The San Antonio Breast Cancer Symposium, SABCS, runs December 8-12, 2020.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program